GNPX Stock Analysis: Buy, Sell, or Hold?
GNPX - Genprex, Inc. Common Stock
$4.75
-1.24 (-20.70%)
▼
5d:
-38.59%
30d:
+724.65%
90d:
+417.43%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When GNPX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GNPX is down 38.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GNPX is down 38.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GNPX is currently trading at $4.75, which is considered fair relative to its 30-day fair value range of $0.34 to $7.20.
Technical Outlook: Technically, GNPX is in a strong downtrend. The price is currently testing key support at $4.65. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 20.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.50 (+57.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GNPX is in a strong downtrend. The price is currently testing key support at $4.65. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 20.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.50 (+57.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.34 -
$7.20
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-20.7%)
- BULLISH: Trading 57.9% below Wall St target ($7.50)
- WARNING: Recommendation downgraded due to -38.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.34 -
$7.20
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.65
Resistance Level
$8.50
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.13
Wall Street Target
$7.50
(+57.9%)
Share & Embed Analysis
Last updated: August 04, 2026 12:06 AM ET
Data refreshes hourly during market hours. Next update: 1:06 AM
Data refreshes hourly during market hours. Next update: 1:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GNPX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Brent M Longnecker
SELL
8 shares
2026-04-14
Brent M Longnecker
SELL
10 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
